Publication

In vitro Ruthenation of Human Breast Cancer Suppressor Gene 1 (BRCA1) by the Antimetastasis Compound RAPTA-C and Its Analogue CarboRAPTA-C

Related publications (68)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

In vitro Ruthenation of Human Breast Cancer Suppressor Gene 1 (BRCA1) by the Antimetastasis Compound RAPTA-C and Its Analogue CarboRAPTA-C

Graph Chatbot

Chat with Graph Search

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity

Solute carriers (SLCs) in cancer

Selective Delivery of an Anticancer Drug with Aptamer-functionalized Liposomes to Breast Cancer Cells in vitro and in vivo

Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer cell death

Very small photoluminescent gold nanoparticles for multimodality biomedical imaging

Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure arene ligands

Cytotoxic gold compounds: synthesis, biological characterization and investigation of their inhibition properties of the zinc finger protein PARP-1

Naphthalimide-tagged ruthenium-arene anticancer complexes: combining coordination with intercalation

Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells

Altered DNA Binding and Amplification of Human Breast Cancer Suppressor Gene BRCA1 Induced by a Novel Antitumor Compound, [Ru(eta(6)-p-phenylethacrynate)Cl-2(pta)]